Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 72.24% is 21% below its 5-year average of 91.48%, near the high end of its 5-year range (-488.97%–100.00%).
15.89% below its 12-month average of 85.89%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
72.24%
GROSS MARGIN AVG TTM
85.89%
GROSS MARGIN AVG 3Y
100.00%
GROSS MARGIN AVG 5Y
91.48%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-15.89%
CURRENT VS 3Y AVG
-27.76%
CURRENT VS 5Y AVG
-21.03%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+75.32%
vs the sector median at left
TScan Therapeutics, Inc.
Market Cap
$16.82M
Gross Margin
72.24%
TTM Avg
85.89%
3Y Avg
100.00%
5Y Avg
91.48%
Market Cap
$16.84M
Gross Margin
0.00%
TTM Avg
-52.16%
3Y Avg
-139.89%
5Y Avg
-776.52%
Market Cap
$16.74M
Gross Margin
99.63%
TTM Avg
49.76%
3Y Avg
72.18%
5Y Avg
92.05%
Market Cap
$16.64M
Gross Margin
21.95%
TTM Avg
11.59%
3Y Avg
17.76%
5Y Avg
20.87%
Market Cap
$17.07M
Gross Margin
-354.93%
TTM Avg
-228.26%
3Y Avg
-369.25%
5Y Avg
-249.00%
Market Cap
$16.52M
Gross Margin
-88.25%
TTM Avg
-11.22%
3Y Avg
9.24%
5Y Avg
11.19%
Market Cap
$17.31M
Gross Margin
-334.26%
TTM Avg
-117.13%
3Y Avg
-347.18%
5Y Avg
-222.70%
Market Cap
$17.39M
Gross Margin
10.27%
TTM Avg
10.01%
3Y Avg
10.00%
5Y Avg
11.56%
Market Cap
$15.78M
Gross Margin
0.00%
TTM Avg
-3731.89%
3Y Avg
-2384.22%
5Y Avg
-1567.12%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TScan Therapeutics, Inc. (TCRX) | $16.82M | 72.24% | 85.89% | 100.00% | 91.48% |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.84M | 0.00% | -52.16% | -139.89% | -776.52% |
| Palatin Technologies, Inc. (PTN)vs › | $16.74M | 99.63% | 49.76% | 72.18% | 92.05% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.64M | 21.95% | 11.59% | 17.76% | 20.87% |
| PAVmed Inc. (PAVM)vs › | $17.07M | -354.93% | -228.26% | -369.25% | -249.00% |
| Dyadic International, Inc. (DYAI)vs › | $16.52M | -88.25% | -11.22% | 9.24% | 11.19% |
| Lipocine Inc. (LPCN)vs › | $17.31M | -334.26% | -117.13% | -347.18% | -222.70% |
| Cosmos Health Inc. (COSM)vs › | $17.39M | 10.27% | 10.01% | 10.00% | 11.56% |
| BioCardia, Inc. (BCDA)vs › | $15.78M | 0.00% | -3731.89% | -2384.22% | -1567.12% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.68M | 107.54% | 50.00% | 25.00% | 16.67% |
Gross Margin
72.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 29.43% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 82.25% |
| 2023-09-30 | 100.00% |
| 2023-06-30 | 100.00% |
| 2023-03-31 | 100.00% |
| 2022-12-31 | 52.05% |
| 2022-09-30 | 100.00% |
| 2022-06-30 | -257.35% |
| 2022-03-31 | -386.26% |
| 2021-12-31 | -341.77% |
| 2021-09-30 | -488.97% |
| 2021-06-30 | -279.25% |
| 2021-03-31 | -262.06% |
| 2020-12-31 | -650.19% |
| 2020-09-30 | -1904.48% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
